Halozyme (HALO): Customer Relationships That Drive a Royalty-and-Device Business

Halozyme operates a hybrid commercial model built around licensing its ENHANZE drug‑delivery technology and selling complementary devices and proprietary products (XYOSTED, Hylenex). The company monetizes through upfront fees, development and sales milestones, royalties on partner product sales, and device supply agreements — a structure that converts partner commercial success into recurring royalty cash flow while capturing margin on hardware and direct product sales.

If you evaluate HALO’s franchise, review this map of customer relationships and the contractual signals that determine revenue durability and concentration. For additional company intelligence, visit https://nullexposure.com/.

The operating blueprint — licensing first, commercialization second

Halozyme is a licensor-first business whose economics depend on partners taking ENHANZE‑enabled formulations to market. The company’s 10‑K describes revenue sources as (i) royalties from licenses, (ii) collaborative agreements, and (iii) product sales, signaling a deliberate mix of low‑touch recurring income and higher‑margin manufacturing/sales revenue. The firm also acts as manufacturer and seller for select device programs, which gives it exposure to supply‑chain and distribution dynamics as well as product liability and regulatory compliance.

Contracting posture: predominantly licensing and long‑term supply arrangements with milestone and royalty linkages; the company discloses significant unfulfilled purchase orders expected to deliver through 2026, indicating multi‑year performance obligations (company 10‑K, FY2024).
Concentration: Halozyme reports that a single partner (Partner A) accounted for over 40% of revenue in 2024, demonstrating material customer concentration that amplifies partner outcomes on Halozyme’s top line (company filings).
Criticality: ENHANZE is the company’s core product; royalty flows from blockbusters such as DARZALEX SC, PHESGO and VYVGART Hytrulo drive the majority of royalty revenue (earnings call Q4 2025; FY2024 10‑K).
Maturity mix: the portfolio spans established commercial blockbusters and earlier stage pilots, creating both predictable royalties and upside from pipeline partners.

Explore strategic signals and partner detail at https://nullexposure.com/.

Customer map — who does what and why it matters

Below are every partner named in Halozyme’s customer‑scope results, with a concise plain‑English description and the source used.

Teva Pharmaceutical Industries, Ltd.

Halozyme has commercialized auto‑injector products with Teva, including multi‑dose pen platforms and an exclusive agreement for epinephrine auto‑injectors in North America; Teva has historically paid upfront, milestone and royalty consideration tied to product sales (Halozyme Form 10‑K, FY2024).

Otter Pharmaceuticals, LLC

Halozyme signed a license and a December 2021 supply agreement to manufacture and supply the VIBEX auto‑injection system and assemble OTREXUP, positioning Halozyme as both device developer and contract manufacturer for Otter (Halozyme 10‑K FY2024; supply agreement language cited in filings).

Skye (SKYE)

Skye is a new ENHANZE partner announced in 2025‑26, described in analyst and earnings coverage as expanding ENHANZE beyond oncology; public reports highlight recent deals with Takeda, Merus and Skye as incremental growth drivers (Alphastreet and H.C. Wainwright coverage, FY2026 commentary).

Roche (RHHBY)

Roche’s PHESGO is one of the largest ENHANZE‑enabled products, delivering meaningful royalty revenue to Halozyme (Halozyme Q4 2025 earnings call transcript; TradingView reporting, FY2026). Roche also continues to nominate new ENHANZE targets, sustaining partner pipeline activity (earnings call Q4 2025).

argenx (ARGX)

argenx’s VYVGART Hytrulo co‑formulated with ENHANZE grew rapidly in 2025 and contributed substantial royalty income, with Halozyme reporting significant year‑over‑year increases tied to argenx adoption and prefilled syringe launches that expanded access (Halozyme Q4 2025 earnings call transcript; InsiderMonkey reporting, FY2026).

Johnson & Johnson (JNJ)

J&J’s subcutaneous DARZALEX (daratumumab) using ENHANZE is a material royalty source for Halozyme, producing large annual royalty receipts as DARZALEX sales expanded; analysts and earnings transcripts tie Halozyme’s royalty growth directly to DARZALEX performance (TradingView and earnings call Q4 2025; Intellectia preview, FY2026).

Viatris (VTRS)

Halozyme signed a commercial licensing and supply agreement with Viatris for a small‑volume auto‑injector, reflecting the company’s strategy to monetize device IP alongside ENHANZE licensing (Halozyme Q4 2025 earnings remarks; news coverage FY2026).

Takeda (TAK)

Takeda uses ENHANZE in products such as HYQVIA and has secured approvals in multiple regions, including Japan, supporting regional revenue expansion in APAC for Halozyme through partner commercialization (company filings and news on Takeda approvals, cited in constraints; Alphastreet/InsiderMonkey commentary, FY2026).

Bristol Myers Squibb (BMY)

BMS launched OPDIVO Qvantig (subcutaneous nivolumab with ENHANZE), generating both milestone payments and ongoing royalties, and BMS reported meaningful quarterly sales from the subcutaneous product after a permanent J‑code issuance in mid‑2025 (earnings call Q4 2025; news sentiment, FY2026).

Merus (MRUS)

Merus is characterized as an earlier‑stage ENHANZE partner in Halozyme materials; company commentary and news note new deals with Merus as part of 2025‑26 commercial expansion that broadens ENHANZE into additional therapeutic classes (Q4 2025 earnings call; Alphastreet FY2026 coverage).

For a consolidated view and further analysis, see https://nullexposure.com/.

What the contractual constraints tell investors

Halozyme’s constraint signals shape risk and upside in predictable ways:

Licensing is dominant and long‑dated. Multiple filings note that royalties and licensing fees are the core revenue stream and that several agreements include upfront payments, milestones and royalties — a classic licensor revenue model (company 10‑K, FY2024). Long‑term delivery obligations and unfulfilled purchase orders through 2026 confirm multi‑year revenue recognition.
Material concentration and variable spend bands. The company discloses a partner accounting for >40% of revenue in 2024 and lists milestone bands ranging from <$10m to >$100m, indicating significant dependence on a handful of large partners for near‑term cash flows.
Role diversity reduces single‑point failure but adds complexity. Halozyme operates as licensor, seller, manufacturer and distributor, which diversifies revenue but increases regulatory, manufacturing and commercial execution risk (company filings).
Market access and reimbursement are real risk vectors. Halozyme explicitly calls out government and payer reimbursement changes (CMS policy, Medicare/Medicaid) as material risks to partner product uptake and Halozyme’s royalty potential.
Currency and patent exposures are material. The company hedges Swiss franc royalties and has patent arrangements affecting royalty rates (company 10‑K and disclosures).

Investment takeaway and next steps

Halozyme’s model converts partner commercial success into high‑leverage royalty revenue, supplemented by device manufacturing and proprietary product sales. The return profile is asymmetric: upside if blockbusters continue to grow and partners add ENHANZE targets; downside concentrated if a major partner’s trajectory reverses. Monitor partner sales trends (DARZALEX, PHESGO, VYVGART Hytrulo), milestone recognition, and the company’s reliance on a small number of counterparties.

If you want a deeper counterparty analysis or updated partner revenue mapping, visit https://nullexposure.com/ for tailored research and alerts. For direct access to HALO relationship intelligence and constraint summaries, go to https://nullexposure.com/ before making allocation decisions.

HALO customer relationships